Negin Biglari, Ali Fotouhi, Mohammad Sadegh Soltani-Zangbar, Ali Aghebati-Maleki, Sanam Nami, Amin Abasi, Mohammed Hamarashid Abdalkarim, Arash Mohamadi, Leili Aghebati-Maleki
{"title":"Postbiotic-Mediated Regulation of Inflammation in Osteoarthritis: An In Vitro Study","authors":"Negin Biglari, Ali Fotouhi, Mohammad Sadegh Soltani-Zangbar, Ali Aghebati-Maleki, Sanam Nami, Amin Abasi, Mohammed Hamarashid Abdalkarim, Arash Mohamadi, Leili Aghebati-Maleki","doi":"10.1007/s12247-026-11078-9","DOIUrl":"10.1007/s12247-026-11078-9","url":null,"abstract":"<div><h3>Background</h3><p>Until now, no definitive treatment has been introduced for osteoarthritis. In this study, due to their unique characteristics, we intend to use the anti-inflammatory properties of postbiotics to control inflammation.</p><h3>Methodology</h3><p>The K4IM cell line was cultured in a DMEM culture medium. After 24 h, 10 ng/ml TNF-α was added. Postbiotics were prepared with a standard protocol. Then, the optimal concentration of postbiotics was added to the cells. Finally, the cells were collected, their total RNA was extracted, and the cDNA was synthesized. The target genes’ mRNA expression level was checked by the qRT-PCR method. Pro and anti-inflammatory cytokines concentration was assessed using the ELISA technique.</p><h3>Results</h3><p>In the cell line related to osteoarthritis, after crossing the cells with postbiotics extracted from yeasts, we had a significant decrease in inflammatory markers such as IL-1β, IL-6, IL-8, and CXCL-8 (<i>p</i> = 0.008, 0.013, 0.02, and 0.015, respectively), which resulted in gene expression levels being aligned. Meanwhile, anti-inflammatory markers such as IL-10, IL-4, and VEGF showed a significant increase in gene expression levels after the effect of postbiotics (<i>p</i> = 0.037, 0.045, and 0.041, respectively). IL-6 and IL-8 concentrations were decreased after the impact of postbiotics (<i>p</i> = 0.025 and 0.042, respectively), whereas IL-10 concentration increased (<i>p</i> = 0.038). Our investigation revealed a significant downregulation of miR-155 and miR-92a expression (<i>p</i> = 0.031 and 0.011, respectively), whereas miR-10a (<i>p</i> = 0.021) and miR-150 (<i>p</i> = 0.022) expression was upregulated after incubated with postbiotics.</p><h3>Conclusion</h3><p>Our results showed that the anti-inflammatory properties of postbiotics can control inflammation due to their unique characteristics.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qusai Malak, Rupa Mazumder, Anjna Rani, Abhijit Debnath
{"title":"Ursolic Acid and Fisetin Co-loaded Dual Phytoconstituent Cryptosomes: A Combinatorial Nanotherapeutic Approach for Retinoblastoma","authors":"Qusai Malak, Rupa Mazumder, Anjna Rani, Abhijit Debnath","doi":"10.1007/s12247-026-11103-x","DOIUrl":"10.1007/s12247-026-11103-x","url":null,"abstract":"<div><h3>Introduction</h3><p>Retinoblastoma is a rare pediatric intraocular malignancy for which conventional therapies often cause significant adverse effects. This study aimed to develop and optimize a targeted ocular drug delivery system containing ursolic acid and fisetin-loaded cryptosomes for retinoblastoma treatment.</p><h3>Methods</h3><p>Molecular docking using iDock software evaluated the interaction of selected phytoconstituents with the PD-1 receptor. Ursolic acid and fisetin were chosen based on favorable docking scores and anticancer potential. Cryptosomes were prepared by thin-film hydration and optimized using a two factors at three level central composite design. Characterization included particle size, zeta potential, entrapment efficiency, scanning electron microscopy, differential scanning calorimetry, ex vivo permeability, in vitro release, and stability studies.</p><h3>Results</h3><p>Both ursolic acid and fisetin exhibited strong binding affinities toward the PD-1 receptor. Optimized cryptosomes showed nanoscale vesicle formation, high entrapment efficiency, suitable zeta potential, and sustained/controlled corneal permeation. Ex vivo studies demonstrated enhanced ocular permeation and prolonged drug retention. Compatibility and stability assessments confirmed the absence of drug–excipient interactions and maintained physical stability during storage.</p><h3>Conclusion</h3><p>The optimized dual-drug cryptosomal formulation improved ocular delivery through efficient encapsulation, sustained release, enhanced permeability, and stability. Incorporation of phytoconstituents with predicted PD-1 binding affinity may provide a combinatorial anticancer effect, supporting further preclinical investigation of this approach for retinoblastoma therapy.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Coloading of Mangiferin and Capecitabine in Niosomes: A Novel Strategy for Improved Breast Cancer Treatment","authors":"Vidya Sabale, Ashwini Ingole, Amol Warokar, Prafulla Sabale","doi":"10.1007/s12247-026-11082-z","DOIUrl":"10.1007/s12247-026-11082-z","url":null,"abstract":"<div><h3>Purpose</h3><p>In this study, coloaded niosomes containing mangiferin (Mg) and capecitabine (Cap) were prepared using thin film hydration for the treatment of breast cancer. Mangiferin is a xanthone possessing anticancer potential, whereas capecitabine is an FDA-approved drug for breast cancer treatment.</p><h3>Method</h3><p>The coloaded niosomes were optimized using a 3<sup>2</sup>-factorial design with particle size and entrapment efficiency as dependent variables. The optimized batch (CM2), after preliminary evaluation, was further characterized for zeta potential, cumulative drug release, crystallinity (XRD), and drug-excipient interactions (FTIR and DSC).</p><h3>Results</h3><p>The optimized batch achieved the particle size (PS) of 428 nm and zeta potential (ZP) of -22.9 mV, and an entrapment efficiency of 67.1 % for mangiferin and 80.03 % for capecitabine. The coloaded niosomes exhibited sustained drug release, achieving 75.8 % for mangiferin and 90.2 % for capecitabine within 24 h, consistent with Fickian diffusion kinetics. MTT assay on MCF-7 cell lines proved enhanced cytotoxicity of the coloaded niosomes (60.41 µg/mL) compared to pure drugs. The enhanced bioavailability of both drugs was confirmed by an increase in C<sub>max</sub> of mangiferin and capecitabine by 5.66-fold and 2.026-fold, respectively, due to their encapsulation within niosomes.</p><h3>Conclusion</h3><p>Thus, the coloaded niosomes provide a promising strategy for the effective treatment of breast cancer.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Quercetin and Mirtazapine Co-Encapsulated Nanoparticles Fostered Protection Against CUMS-Induced Depression Associated Inflammation","authors":"Sailesh Gupta, Rajshekher Upadhyay, Kaisar Raza, Tanim Aijaz, Lokesh Kaushik, Madhuri Desavathu","doi":"10.1007/s12247-026-11097-6","DOIUrl":"10.1007/s12247-026-11097-6","url":null,"abstract":"<div><p>Major depressive disorder is the most common and prevalent depressive disorder, affecting about 300 million individuals globally. One of the contributing factors can be central inflammation associated with depression. While conventional treatment only targets monoamine imbalance, recent studies suggest that oxidative stress and neuroinflammation play a vital role in the pathophysiology of major depressive disorder. In this context, the current study aimed to target both monoamine disturbance and oxidative stress by intranasally delivering co-encapsulated mirtazapine and quercetin PEGylated solid lipid nanoparticle. The microemulsion technique was used to prepare nanoparticles, and was optimized based on entrapment efficiency. The optimized formulation after PEGylation demonstrated high entrapment efficiency (91.05 ± 0.089% for mirtazapine and 99.88 ± 0.01% for quercetin), nanoscale particle size (35.04 ± 1.0 nm), a polydispersity index (PDI) of 0.464, and a near-neutral zeta potential (− 9.14 ± 1.10 mV). In-vitro release study showed controlled and sustained drug release, whereas ex vivo permeation study showed improved nasal permeation of quercetin, while mirtazapine showed lower permeation from the PEGylated solid lipid nanoparticles compared to pure drugs. In a chronic unpredictable multiple stress-induced depression, intranasal treatment significantly decreases immobility time in the forced swim and tail suspension test, markedly increases sucrose preference, and further significantly decreases nitric oxide and malondialdehyde levels, indicating improvement in depressive-like behaviour. Furthermore, histological investigation of goat nasal tissue and mice’s vital organs provided preliminary evidence of tissue tolerability under the study conditions. Overall, administering Mirtazapine-Quercetin co-loaded PEGylated solid lipid nanoparticles via the intranasal route is a promising method of managing depression and associated inflammation.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Damian McCarthy, Dermot McMorrow, Amol Ganjare, Vivek Ranade, Conor T. McCarthy, Eoin P. Hinchy
{"title":"A Risk-Based Digital Validation Workflow for Advanced Process Control in GMP-Regulated Manufacturing: A Model-Based Approach Demonstrated Through pH Control","authors":"Damian McCarthy, Dermot McMorrow, Amol Ganjare, Vivek Ranade, Conor T. McCarthy, Eoin P. Hinchy","doi":"10.1007/s12247-026-11080-1","DOIUrl":"10.1007/s12247-026-11080-1","url":null,"abstract":"<div><h3>Purpose</h3><p>This paper addresses the “digital validation chasm” in the life sciences sector, where stringent Good Manufacturing Practice (GMP) and Good Automated Manufacturing Practice (GAMP) 5 regulations often hinder the adoption of advanced control strategies. The research proposes a unified, risk-based digital validation workflow designed to integrate process understanding and model-based design with Quality Risk Management (QRM) and lifecycle-oriented validation principles, facilitating the transition toward Pharma 4.0.</p><h3>Methods</h3><p>The proposed workflow was demonstrated through the development of a Model Predictive Controller (MPC) for pH regulation. A data-driven Hammerstein–Wiener model was identified from experimental data to inform the MPC tuning within MATLAB/Simulink. A process- and control-focused Failure Mode and Effects Analysis (FMEA) was used to identify and prioritise relevant failure modes and to inform requirements and verification scope. Requirements-based verification was embedded directly into the engineering lifecycle using automated test harnesses to generate traceable evidence against defined requirements and acceptance criteria. Finally, the controller was deployed as IEC 61131-3 structured-text code on an industrial programmable logic controller (PLC).</p><h3>Results</h3><p>Experimental testing evaluated MPC performance across steady-state, disturbance rejection, and dynamic setpoint scenarios. The use of automated testing and simulation-based verification provided reproducible validation evidence linked to the identified risks and functional requirements. Experimental characterisation and system identification provided a data-driven representation of process behaviour that informed both controller development and risk-informed verification planning.</p><h3>Conclusion</h3><p>The study provides a practical proof-of-concept implementation of a workflow for bridging the gap between traditional validation practices and modern digital engineering. By integrating process understanding, QRM, model-based design, automated verification and deployment within a unified lifecycle, the approach demonstrates how advanced process-control development can be structured in alignment with risk-based and lifecycle-oriented validation principles relevant to regulated manufacturing.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nidhi Chaturvedi, Rupa Mazumder, Anmol Dogra, Anjna Rani, Ashish Joshi
{"title":"Enhanced Brain Biodistribution of Quercetin and Rutin Co-Loaded Pegylated PLGA Nanoparticles Via Intranasal Delivery for Neuroblastoma Therapy","authors":"Nidhi Chaturvedi, Rupa Mazumder, Anmol Dogra, Anjna Rani, Ashish Joshi","doi":"10.1007/s12247-026-11088-7","DOIUrl":"10.1007/s12247-026-11088-7","url":null,"abstract":"<div><h3>Purpose</h3><p>Neuroblastoma (NB) is a frequent malignancy in children detected outside the brain with its feature of frequent relapses, poor outcome, and very high toxicity of standard chemotherapy. In order to treat NB, this effort aimed to develop and optimize PLGA-PEG-PLGA nanoparticles loaded with rutin and quercetin for nasal delivery to the brain.</p><h3>Methods</h3><p>The nanoparticle formulation was prepared by the method of nanoprecipitation and optimized by Central Composite Design (CCD) with PLGA and stabilizer (Poloxamer 188) concentrations as independent variables. After optimization, the polymeric formulation was assessed using particle dimensions, polydispersity index, zeta kinetic potential, entrapment efficiency (EE), SEM, FTIR, and in vitro drug release studies. The produced formulation’s anticancer efficacy was investigated using the MTT test on neuroblastoma cells, and biodistribution studies in Wistar rats after nasal administration were carried out.</p><h3>Results</h3><p>The nanoparticles had a zeta potential of -14.34 mV, with particle sizes varying between 213.7 and 245.8 nm, and an acceptable particle size distribution (0.218–0.258). For quercetin and rutin, the drug loading efficiency was determined to be 80% and 82%, respectively. FTIR analysis also showed that there was no drug-excipient interaction. With a cumulative percentage release of 82.3% from nanoparticles and 68.9% from the plain solution in a 24-hour period, the in vitro drug release research was shown to fit the Hixson-Crowell model. When compared to free drug, nanoparticles had a considerable cytotoxic impact on SH-SY5Y cells, with an IC<sub>50</sub> value of 568.1 ± 0.12 µg/ml. When compared to mucoadhesive suspension, the concentration of quercetin and rutin in brain tissue increased by 2.35 and 2.40 times, respectively, in an in vivo investigation of mucoadhesive nanoparticles through intranasal delivery.</p><h3>Conclusion</h3><p>The optimized PLGA-PEG-PLGA nanoparticle formulation offers a stable, sustained-release intranasal delivery system for co-administration of quercetin and rutin, with enhanced anticancer cell line efficacy relative to the free drugs, supporting further preclinical evaluation for NB treatment.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhihao Shu, Yang Huang, Jing Liu, Jintao Guo, Siyi Wu, Meiying Ning
{"title":"Machine Learning-Assisted Predictive Formulation Modeling for Segmented Combination Vaginal Rings: Construction and Validation","authors":"Zhihao Shu, Yang Huang, Jing Liu, Jintao Guo, Siyi Wu, Meiying Ning","doi":"10.1007/s12247-026-11027-6","DOIUrl":"10.1007/s12247-026-11027-6","url":null,"abstract":"<div><p>The vaginal ring represents an innovative sustained-release drug delivery system in the field of women’s reproductive health, demonstrating significant clinical value. However, its formulation development remains constrained by a traditional “trial-and-error” empirical approach, which often requires substantial cost investment for studies involving multiple factors and levels. To address evolving patient needs and diverse drug properties, this research investigates the application of machine learning algorithms in pharmaceutical development, with a specific focus on the development and optimization of vaginal ring formulations. A segmented combination(ATZ/LNG) IVR for the treatment of endometriosis is successfully fabricated and subjected to pre-formulation studies. Furthermore, the XGBoost machine learning model is selected and trained for the vaginal ring formulation. The feasibility of the developed machine learning-assisted predictive formulation framework was experimentally validated. In response to the high costs associated with the conventional trial-and-error method in formulation development, this study leveraged research on the complex formulation of the intravaginal ring (IVR) dosage form to develop an AI-based predictive model. It suggests the feasibility of AI-assisted pharmaceutical development and proposes a novel methodology for formulation research.</p><h3>Graphical abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12247-026-11027-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dhivya Viswanathan, Fahad M Alshabrmi, Mahdi H. Alsugoor, Naif ALSuhaymi, Muthu Thiruvengadam, Rajakumar Govindasamy
{"title":"Pharmaceutical Development of Apigenin–Berberine-Loaded PLGA Hydrogel Nanocomposite for Antioxidant and Anti-Inflammatory Osteoarthritis Therapy","authors":"Dhivya Viswanathan, Fahad M Alshabrmi, Mahdi H. Alsugoor, Naif ALSuhaymi, Muthu Thiruvengadam, Rajakumar Govindasamy","doi":"10.1007/s12247-026-11094-9","DOIUrl":"10.1007/s12247-026-11094-9","url":null,"abstract":"<div><h3>Purpose</h3><p>Osteoarthritis (OA) is driven by interlinked oxidative stress, ferroptosis and inflammatory cartilage catabolism, yet no disease-modifying pharmacotherapy has been approved. Apigenin (AP) and berberine (BB) are chondroprotective phytochemicals whose therapeutic use is constrained by poor aqueous solubility, low bioavailability and rapid clearance from the joint cavity. This study aimed to develop and characterise an AP/BB-loaded PLGA hydrogel nanocomposite (AP/BB@PLGA) for sustained local antioxidant and anti-inflammatory therapy.</p><h3>Methods</h3><p>AP/BB-PLGA nanoparticles were prepared by a modified W1/O/W2 double-emulsion solvent-evaporation method at three AP: BB molar ratios (1:1, 2:1 and 1:2) and dispersed in a PLAG hydrogel. The nanocomposite was characterised by dynamic light scattering, zeta potential, scanning electron microscopy, FTIR spectroscopy, drug release, swelling and degradation studies, and evaluated in erastin-challenged chondrocytes and MC3T3-E1 pre-osteoblasts. </p><h3>Results</h3><p>The AP: BB 2:1 formulation was optimal (175 nm; PDI 0.21; −28 mV; encapsulation efficiency 85% for AP and 80% for BB). Release was burst-free, reaching 90% for AP and 80% for BB at 96 h, with 1,150–1,200% swelling and 47% mass loss at 28 days. AP/BB@PLGA was cytocompatible, restored chondrocyte viability and migration, normalised reactive oxygen species and malondialdehyde, restored GSH, CAT and SOD, suppressed MMP3, MMP9, MMP13, iNOS, ADAMTS5, IL-1β, IL-6 and TNF-α, and increased COL2A1, IL-10, IL-4, GPX4 and SLC7A11 while lowering ACSL4. </p><h3>Conclusion</h3><p>AP/BB@PLGA delivers sustained dual-drug release together with coordinated antioxidant, anti-ferroptotic and anti-inflammatory activity across the bone–cartilage unit, supporting its development as a biomaterial disease-modifying platform for osteoarthritis.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Design and Development of Advanced Biocompatible Hydrogels Loaded with Curcumin-propolis-rGO for Burn Wound Healing Applications","authors":"Amir Nezami Asl, Abolfazl Akbarzadeh, Amirreza Hajati Ziabari, Fatemeh Yarmohammadi, Negar Karimi Hajishoreh","doi":"10.1007/s12247-026-11087-8","DOIUrl":"10.1007/s12247-026-11087-8","url":null,"abstract":"<div><p>Burn injuries compromise skin function leading to delayed healing and infection risk. This study developed an alginate (ALG) hydrogel incorporating curcumin (Cur), propolis(Pro), and reduced graphene oxide (rGO) to enhance burn wound repair. Structural analyses (FTIR, SEM) confirmed successful integration within a porous 3D scaffold. In vitro, the hydrogel showed low cytotoxicity and potent antibacterial action against <i>Staphylococcus</i> aureus and <i>Pseudomonas aeruginosa</i>. In vivo, in a Wistar rat full-thickness burn model, the combined hydrogel significantly accelerated epithelialization, improved collagen deposition and alignment, reduced edema, and enhanced angiogenesis compared to controls. The synergistic effects of natural compounds Pro and rGO improved rapid, balanced tissue regeneration. This bioactive hydrogel holds strong potential as a natural, effective wound dressing for burn therapy.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Setayesh Yarahmadi, Sara Nemati, Akram Yarmohamadi
{"title":"Raman Spectroscopic Evaluation of Packaging-Associated Differences in Blow–Fill–Seal and Cold-Fill Ophthalmic Drug Products","authors":"Setayesh Yarahmadi, Sara Nemati, Akram Yarmohamadi","doi":"10.1007/s12247-026-11096-7","DOIUrl":"10.1007/s12247-026-11096-7","url":null,"abstract":"<div><p>This study investigated whether Raman spectroscopy could detect packaging-associated differences in ophthalmic drug formulations packaged using Blow–Fill–Seal (BFS) and conventional Cold-Fill systems and explored their relationship with pharmaceutical stability. Two liquid ophthalmic formulations, dorzolamide hydrochloride/timolol maleate and chloramphenicol, were evaluated in BFS and Cold-Fill packaging systems. Raman spectra were acquired using a 532 nm excitation laser at integration times of 300 and 600 ms, with four replicate measurements for each condition. Raman measurements were performed on aliquots of the ophthalmic formulations transferred from their original BFS and Cold-Fill primary containers into sterile glass vessels. Spectra were processed using asymmetric least-squares baseline correction and vector normalization. Stability was evaluated at 40 ± 2 °C and 75 ± 5% relative humidity at baseline and after 1, 3, and 6 months. Both formulations exhibited comparable principal Raman fingerprints, but reproducible differences in the relative normalized intensities of several Raman bands were observed between BFS- and Cold-Fill-packaged samples. These differences were maintained at both acquisition times. During accelerated storage, Dorzolamide-related impurity B increased to 4.6% at six months in the BFS-packaged formulation, exceeding the specified limit of 2.0%. Chloramphenicol assay decreased from 514 to 445 mg/100 mL and fell slightly below its lower specification limit at six months, whereas the corresponding Cold-Fill samples remained within applicable specifications. Overall, Raman spectroscopy demonstrated potential as a rapid, non-destructive complementary tool for detecting packaging-associated differences in ophthalmic drug products, although a direct causal relationship between Raman spectral changes and pharmaceutical degradation was not established.</p></div>","PeriodicalId":656,"journal":{"name":"Journal of Pharmaceutical Innovation","volume":"22 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149132397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}